Pulmatrix holds special shareholder meeting
PULM•Pulmatrix shareholders approved merger-related stock issuance exceeding 20% of pre-merger shares, a change of control, a possible one-for-two to one-for-10 reverse stock split, and an increase in authorized common stock from 200 million to 250 million shares.
1. Shareholders approve proposals
At a special meeting on October 26, 2026, Pulmatrix shareholders approved merger-related common stock issuance exceeding 20% of pre-merger outstanding shares and authorized the merger-related change of control. They also approved a reverse stock split ranging from one-for-two to one-for-10 and an increase in authorized common stock from 200 million to 250 million shares.
